Related Experiment Video
Updated: Jun 3, 2025
Methods for Experimental Manipulations after Optic Nerve Transection in the Mammalian CNS
Published on: May 12, 2011
Co-targeting of glial activation and inflammation by tsRNA-Gln-i-0095 for treating retinal ischemic pathologies
Ying Zhang1,2,3, Yan Ma1,2, Yu-Ke Ji1,2
1The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, 210000, China.
Abstract:
Ischemic retinopathies are the major causes of blindness, yet effective early-stage treatments remain limited due to an incomplete understanding of the underlying molecular mechanisms. Significant changes in gene expression often precede structural and functional alterations. Transfer RNA (tRNA)-derived small RNAs (tsRNAs) are emerging as novel gene regulators, involved in various biological processes and human diseases. In this study, tsRNA-Gln-i-0095 was identified as a novel regulator, which was significantly upregulated in retinal ischemia/reperfusion (I/R) injury. Reducing the levels of tsRNA-Gln-i-0095 suppressed reactive gliosis, lowered inflammatory cytokine levels, and protected retinal ganglion cells from I/R injury. These effects led to reduced structural and functional damage, inhibited glial activation and inflammation, and enhanced neuronal function. Mechanistically, tsRNA-Gln-i-0095 downregulated the expression of NFIA and TGFBR2 through a miRNA-like mechanism. Collectively, this study highlights the potential of targeting tsRNA-Gln-i-0095 as a novel therapeutic approach to reduce retinal I/R injury and preserve visual function.
Insights
A novel regulator, tsRNA-Gln-i-0095, was found to be upregulated in retinal ischemia/reperfusion injury. Reducing its levels protected retinal ganglion cells and preserved visual function.
Area of Science:
- Ophthalmology
- Molecular Biology
- Genetics
Background:
- Ischemic retinopathies are a leading cause of blindness.
- Current early-stage treatments are limited by incomplete understanding of molecular mechanisms.
- Transfer RNA (tRNA)-derived small RNAs (tsRNAs) are emerging gene regulators in disease.
Purpose of the Study:
- Identify novel molecular regulators in retinal ischemia/reperfusion (I/R) injury.
- Investigate the role of tsRNA-Gln-i-0095 in retinal I/R injury.
- Explore tsRNA-Gln-i-0095 as a potential therapeutic target.
Main Methods:
- Quantification of tsRNA-Gln-i-0095 in retinal I/R injury models.
- Experimental manipulation of tsRNA-Gln-i-0095 levels.
- Assessment of glial activation, inflammation, and neuronal survival.
- Mechanistic analysis of gene expression regulation.
Main Results:
- tsRNA-Gln-i-0095 was significantly upregulated in retinal I/R injury.
- Reducing tsRNA-Gln-i-0095 suppressed reactive gliosis and inflammation.
- tsRNA-Gln-i-0095 protected retinal ganglion cells, reducing structural and functional damage.
- tsRNA-Gln-i-0095 downregulated NFIA and TGFBR2 via a miRNA-like mechanism.
Conclusions:
- tsRNA-Gln-i-0095 is a key regulator in retinal I/R injury.
- Targeting tsRNA-Gln-i-0095 offers a potential therapeutic strategy.
- Modulating tsRNA-Gln-i-0095 can preserve visual function by inhibiting glial activation and inflammation.
